Literature DB >> 19133919

Serum eosinophil granule proteins predict asthma risk in allergic rhinitis.

L P Nielsen1, C G B Peterson, R Dahl.   

Abstract

BACKGROUND: Allergic rhinitis is a common disease, in which some patients will deteriorate or develop asthma. It is important to characterize these patients, thereby offering the possibility for prevention. This study evaluated eosinophil parameters as potential indicators of deteriorating allergic airway disease.
METHODS: The subjects of the study included all patients who suffered seasonal allergic rhinitis and had participated in a study 6 years earlier, in which blood eosinophils, serum eosinophil cationic protein (ECP) serum eosinophil peroxidase (EPO), nasal lavage ECP and nasal lavage EPO levels were measured. Patients in the present study were interviewed on occurrence of rhinitis symptoms during the last season, rhinitis outside season, asthma-like symptoms and asthma diagnosis, and were skin-prick tested for common aeroallergens. Eosinophil parameters from the study 6 years earlier were then tested for the ability to predict occurrence of new allergies, worsening of rhinitis and occurrence of asthma.
RESULTS: Forty-four patients participated in the study. In four patients seasonal rhinitis symptoms had deteriorated, 10 had experienced perennial rhinitis symptoms, 14 reported asthma-like symptoms and seven had been diagnosed with asthma. Thirteen had developed additional sensitization. Patients developing asthma-like symptoms compared with patients with no such symptoms had significantly higher serum ECP (16.7 microg/l vs 8.2 microg/l; P < or = 0.01) and serum EPO (17.9 microg/l vs 8.8 microg/l; P < or = 0.05). Results were similar, considering patients diagnosed with asthma. Blood eosinophils and nasal lavage parameters were not related to development of asthma and asthma-like symptoms. No eosinophil parameter was related to deterioration of rhinitis or additional sensitization.
CONCLUSION: Serum ECP and EPO in patients with seasonal rhinitis demonstrated a high predictive ability for later development of asthma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19133919     DOI: 10.1111/j.1398-9995.2008.01869.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  7 in total

1.  PI3-kinase regulates eosinophil and neutrophil degranulation in patients with allergic rhinitis and allergic asthma irrespective of allergen challenge model.

Authors:  Mary Kämpe; Maria Lampinen; Ingrid Stolt; Christer Janson; Gunnemar Stålenheim; Marie Carlson
Journal:  Inflammation       Date:  2012-02       Impact factor: 4.092

2.  The Beneficial Effects of Hydrogen-Rich Saline Irrigation on Chronic Rhinitis: A Randomized, Double-Blind Clinical Trial.

Authors:  Ling Jin; Kai Fan; Shiwang Tan; Shangxi Liu; Qin Ge; Yang Wang; Zisheng Ai; Shaoqing Yu
Journal:  J Inflamm Res       Date:  2022-07-15

Review 3.  Which biomarkers are effective for identifying Th2-driven inflammation in asthma?

Authors:  Zuzana Diamant; Ellen Tufvesson; Leif Bjermer
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

4.  The Iron Chelator and Anticancer Agent Dp44mT Relieves Allergic Inflammation in Mice With Allergic Rhinitis.

Authors:  Hee-Yun Kim; Na-Ra Han; Hyung-Min Kim; Hyun-Ja Jeong
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

5.  Hydrogen-rich saline attenuates eosinophil activation in a guinea pig model of allergic rhinitis via reducing oxidative stress.

Authors:  Shaoqing Yu; Chuanliang Zhao; Na Che; Lin Jing; Rongming Ge
Journal:  J Inflamm (Lond)       Date:  2017-01-13       Impact factor: 4.981

6.  Interleukin-13 in Asthma and Other Eosinophilic Disorders.

Authors:  Emma Doran; Fang Cai; Cécile T J Holweg; Kit Wong; Jochen Brumm; Joseph R Arron
Journal:  Front Med (Lausanne)       Date:  2017-09-19

7.  Rapid Evolution of Primate Type 2 Immune Response Factors Linked to Asthma Susceptibility.

Authors:  Matthew F Barber; Elliott M Lee; Hayden Griffin; Nels C Elde
Journal:  Genome Biol Evol       Date:  2017-06-01       Impact factor: 3.416

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.